ClinicalTrials.gg
CompletedNCT03556891Updated Oct 2, 2025Results posted

Pivotal Study of eCoin for Overactive Bladder With Urgency Urinary Incontinence

An interventional study of eCoin Tibial Nerve Stimulation in Overactive Bladder, Urge Incontinence and Incontinence, Urinary, sponsored by Valencia Technologies Corporation. Completed at 15 sites in United States. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2025-10-02.

Sponsored by Valencia Technologies Corporation · Not applicable, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
133
Allocation
Not applicable
Ages
18 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 333 studies in Urinary Bladder, Overactive with a site in United States — 40 open to participants now, 48 under way, 2 of them phase 3. Urinary Bladder, Overactive · United States.

Enrollment
104th of 288
133 · median 66
Started
2018
with 19 others
No phase
113 of 333
20 open now
Registered
194th of 333
by date

Among the 333 studies in Urinary Bladder, Overactive with a site in United States, this one is the 104th largest by enrollment of the 288 interventional ones that give a count, is one of 20 that started in 2018, is one of 113 with no phase, and was the 194th registered.

Urinary Bladder, Overactive

860 studies on the registry are indexed under Urinary Bladder, Overactive; 128 are open to participants now.

Browse Urinary Bladder, Overactive studies →

Open to participants now

40 of the 333 studies in Urinary Bladder, Overactive with a site in United States are open now. Recruiting first, the newest first:

35 more — sign in →

All 40 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 75 Urinary Bladder, Overactive studies recruiting now, 45 (60%) set no upper age limit and 16 (21%) stop at 75 or younger; 7 take children under 18; 8 take healthy volunteers.

This study: 18 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 333 studies in Urinary Bladder, Overactive with a site in United States, or all of them as a file.
02

Study summary

This trial is a prospective, multicenter, single-arm study of the safety and effectiveness of eCoinTM tibial nerve stimulation in subjects having overactive bladder (OAB) with urgency urinary incontinence (UUI). The study will evaluate changes from baseline in OAB symptoms as measured by voiding diaries and patient reported-outcomes through 48 weeks of eCoinTM therapy or 52 weeks of implantation.

Read the detailed description

This study enrolled and implanted 133 subjects at 15 sites in the US under the original IDE.

Subjects were given the option to extend out to 3 years post activation, with annual visits at 2 and 3 years post activation (96 and 144 weeks post-activation).

Subjects who are still active in the original IDE study will be offered consecutive enrollment in the post approval study and will be given the option to receive a new implant. Subjects who are no longer active, or have exited the study will be given the option to reenter the study and complete two follow-up visits. Subjects re-entering the study will not have the option to receive a new implant. Post approval follow-up of subjects will occur through the year 5 visit (257 weeks post-activation of their original device). Reimplantation of a new eCoin would not reset their follow-up clock.

03

Conditions studied

  • Overactive Bladder
  • Urge Incontinence
  • Incontinence, Urinary
  • Urinary Urge Incontinence
04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Primary Inclusion Criteria:

  1. Women and men between 18 and 80 years old.
  2. Diagnosis of overactive bladder with urgency urinary incontinence or mixed urge and stress incontinence with a predominant urgency component (selfreported), for at least 6 months.
  3. Individual is without pharmacological treatment of overactive bladder (antimuscarinics and beta-3 agonists).
  4. Individual is intolerant of or has an inadequate response to any of anticholinergics, β3-adrenoceptor agonists, onabotulinumtoxinA, or percutaneous tibial nerve stimulation.

Primary Exclusion Criteria:

  1. Predominant stress urinary incontinence with more than 1/3 stress urinary incontinent episodes when compared to total urinary incontinent episodes.
  2. bladder outlet obstruction.
  3. Clinically significant pelvic organ prolapse beyond the hymenal ring.
  4. Inadequate skin integrity or any evidence of an infection or inflammation in either lower leg.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
133 participants (actual)

Study arms

  • Experimental
    eCoin Tibial Nerve Stimulation

    Device: eCoin Tibial Nerve Stimulation

Interventions

  • DeviceeCoin Tibial Nerve Stimulation

    Subcutaneous stimulation of the tibial nerve using the eCoin device.

06

What researchers measure

Primary outcomes

  1. Percentage of Subjects Experiencing 50% or Better Improvement in Urgency Urinary Incontinence Episodes as Measured by a 3-day Voiding Diary.

    Responder rate

    Time frame: 48 weeks after device activation.

  2. Long-term Safety in All Patients. Percentage of Patients With Device Related Adverse Events.

    All adverse events will be reported in all patients up to 52 weeks after implantation.

    Time frame: 52 weeks after implantation.

Secondary outcomes

  1. Moderate-term Safety in All Patients. Percentage of Patients With Device Related Adverse Events.

    All adverse events will be reported.

    Time frame: 28 weeks after implantation

  2. Moderate-term Effectiveness Data. Percentage of Subjects Experiencing 50% or Better Improvement in Urgency Urinary Incontinence Episodes as Measured by a 3-day Voiding Diary.

    Moderate-term effectiveness data, responder rate

    Time frame: 24 weeks after device activation

  3. Percentage of Subjects Experiencing 50% or Better Improvement in Urgency Urinary Incontinence Episodes as Measured by a 3-day Voiding Diary

    Responder rate

    Time frame: 96 weeks after device activation.

  4. Percentage of Subjects Experiencing 50% or Better Improvement in Urgency Urinary Incontinence Episodes as Measured by a 3-day Voiding Diary.

    Responder rate

    Time frame: 144 weeks after device activation

  5. Percentage of Subjects Experiencing 50% or Better Improvement in Urgency Urinary Incontinence Episodes as Measured by a 3-day Voiding Diary.

    Responder rate

    Time frame: 205 weeks after device activation

  6. Percentage of Subjects Experiencing 50% or Better Improvement in Urgency Urinary Incontinence Episodes as Measured by a 3-day Voiding Diary.

    Responder rate

    Time frame: 257 weeks after device activation

  7. Long-term Safety in All Patients: Percentage of Patients With Device Related Adverse Events.

    All adverse events will be reported in all patients up to 96 weeks after implantation.

    Time frame: 96 weeks after implantation

  8. Long-term Safety in All Patients: Percentage of Patients With Device Related Adverse Events

    All adverse events will be reported in all patients up to 144 weeks after implantation.

    Time frame: 144 weeks after implantation

  9. Long-term Safety in All Patients. Percentage of Patients With Device Related Adverse Events

    All adverse events will be reported in all patients up to 205 weeks after implantation.

    Time frame: 205 weeks after implantation

  10. Long-term Safety in All Patients. Percentage of Patients With Device Related Adverse Events

    All adverse events will be reported in all patients up to 257 weeks after implantation.

    Time frame: 257 weeks after implantation

07

Results

Posted Jul 30, 2021
Limitations and caveats
A limitation of the study was the lack of blinding and comparison. Considering that neuromodulation studies are generally not blinded since the therapy itself is sensed, a control group with a similar safety profile to eCoin could not be achieved. We also acknowledge that a 12-month endpoint provides only medium-term data on the durability of response and future longer follow up data will be needed.

Participant flow

Initial Pivotal Study
Participant flow — Initial Pivotal Study
MilestoneeCoin Tibial Nerve Stimulation
Started133
Completed120
Not completed13
Withdrew: Adverse event4
Withdrew: Mri need3
Withdrew: Device failure1
Withdrew: Death1
Withdrew: Lost to follow-up1
Withdrew: Missing at random1
Withdrew: Missing due to covid1
Withdrew: Protocol violation1
Pivotal Extension Study
Participant flow — Pivotal Extension Study
MilestoneeCoin Tibial Nerve Stimulation
Started105
Completed41
Not completed64
Pivotal Re-extension
Participant flow — Pivotal Re-extension
MilestoneeCoin Tibial Nerve Stimulation
Started31
Completed21
Not completed10

Outcome measures

PrimaryPercentage of Subjects Experiencing 50% or Better Improvement in Urgency Urinary Incontinence Episodes as Measured by a 3-day Voiding Diary.

Responder rate

Time frame:
48 weeks after device activation.
Reported as:
Number · percentage of participants
Percentage of Subjects Experiencing 50% or Better Improvement in Urgency Urinary Incontinence Episodes as Measured by a 3-day Voiding Diary.
percentage of participantseCoin Tibial Nerve Stimulation
Percentage of Subjects Experiencing 50% or Better Improvement in Urgency Urinary Incontinence Episodes as Measured by a 3-day Voiding Diary.68 (60 to 76)
PrimaryLong-term Safety in All Patients. Percentage of Patients With Device Related Adverse Events.

All adverse events will be reported in all patients up to 52 weeks after implantation.

Time frame:
52 weeks after implantation.
Reported as:
Number · percentage of participants
Long-term Safety in All Patients. Percentage of Patients With Device Related Adverse Events.
percentage of participantseCoin Tibial Nerve Stimulation
Long-term Safety in All Patients. Percentage of Patients With Device Related Adverse Events.16
SecondaryModerate-term Safety in All Patients. Percentage of Patients With Device Related Adverse Events.

All adverse events will be reported.

Time frame:
28 weeks after implantation
Reported as:
Number · percentage of participants
Moderate-term Safety in All Patients. Percentage of Patients With Device Related Adverse Events.
percentage of participantseCoin Tibial Nerve Stimulation
Moderate-term Safety in All Patients. Percentage of Patients With Device Related Adverse Events.14
SecondaryModerate-term Effectiveness Data. Percentage of Subjects Experiencing 50% or Better Improvement in Urgency Urinary Incontinence Episodes as Measured by a 3-day Voiding Diary.

Moderate-term effectiveness data, responder rate

Time frame:
24 weeks after device activation
Reported as:
Number · percentage of participants
Moderate-term Effectiveness Data. Percentage of Subjects Experiencing 50% or Better Improvement in Urgency Urinary Incontinence Episodes as Measured by a 3-day Voiding Diary.
percentage of participantseCoin Tibial Nerve Stimulation
Moderate-term Effectiveness Data. Percentage of Subjects Experiencing 50% or Better Improvement in Urgency Urinary Incontinence Episodes as Measured by a 3-day Voiding Diary.69 (61 to 77)
SecondaryPercentage of Subjects Experiencing 50% or Better Improvement in Urgency Urinary Incontinence Episodes as Measured by a 3-day Voiding Diary

Responder rate

Time frame:
96 weeks after device activation.
Reported as:
Number · Percentage of participants
Percentage of Subjects Experiencing 50% or Better Improvement in Urgency Urinary Incontinence Episodes as Measured by a 3-day Voiding Diary
Percentage of participantseCoin Tibial Nerve Stimulation
Percentage of Subjects Experiencing 50% or Better Improvement in Urgency Urinary Incontinence Episodes as Measured by a 3-day Voiding Diary78 (67 to 87)
SecondaryPercentage of Subjects Experiencing 50% or Better Improvement in Urgency Urinary Incontinence Episodes as Measured by a 3-day Voiding Diary.

Responder rate

Time frame:
144 weeks after device activation
Reported as:
Number · Percentage of participants
Percentage of Subjects Experiencing 50% or Better Improvement in Urgency Urinary Incontinence Episodes as Measured by a 3-day Voiding Diary.
Percentage of participantseCoin Tibial Nerve Stimulation
Percentage of Subjects Experiencing 50% or Better Improvement in Urgency Urinary Incontinence Episodes as Measured by a 3-day Voiding Diary.74 (57 to 87)
SecondaryPercentage of Subjects Experiencing 50% or Better Improvement in Urgency Urinary Incontinence Episodes as Measured by a 3-day Voiding Diary.

Responder rate

Time frame:
205 weeks after device activation
Reported as:
Number · Percentage of participants
Percentage of Subjects Experiencing 50% or Better Improvement in Urgency Urinary Incontinence Episodes as Measured by a 3-day Voiding Diary.
Percentage of participantseCoin Tibial Nerve Stimulation
Percentage of Subjects Experiencing 50% or Better Improvement in Urgency Urinary Incontinence Episodes as Measured by a 3-day Voiding Diary.61 (39 to 80)
SecondaryPercentage of Subjects Experiencing 50% or Better Improvement in Urgency Urinary Incontinence Episodes as Measured by a 3-day Voiding Diary.

Responder rate

Time frame:
257 weeks after device activation
Reported as:
Number · Percentage of participants
Percentage of Subjects Experiencing 50% or Better Improvement in Urgency Urinary Incontinence Episodes as Measured by a 3-day Voiding Diary.
Percentage of participantseCoin Tibial Nerve Stimulation
Percentage of Subjects Experiencing 50% or Better Improvement in Urgency Urinary Incontinence Episodes as Measured by a 3-day Voiding Diary.67 (43 to 85)
SecondaryLong-term Safety in All Patients: Percentage of Patients With Device Related Adverse Events.

All adverse events will be reported in all patients up to 96 weeks after implantation.

Time frame:
96 weeks after implantation
Reported as:
Number · Percentage of participants
Long-term Safety in All Patients: Percentage of Patients With Device Related Adverse Events.
Percentage of participantseCoin Tibial Nerve Stimulation
Long-term Safety in All Patients: Percentage of Patients With Device Related Adverse Events.20
SecondaryLong-term Safety in All Patients: Percentage of Patients With Device Related Adverse Events

All adverse events will be reported in all patients up to 144 weeks after implantation.

Time frame:
144 weeks after implantation
Reported as:
Number · Percentage of participants
Long-term Safety in All Patients: Percentage of Patients With Device Related Adverse Events
Percentage of participantseCoin Tibial Nerve Stimulation
Long-term Safety in All Patients: Percentage of Patients With Device Related Adverse Events20
SecondaryLong-term Safety in All Patients. Percentage of Patients With Device Related Adverse Events

All adverse events will be reported in all patients up to 205 weeks after implantation.

Time frame:
205 weeks after implantation
Reported as:
Number · Percentage of participants
Long-term Safety in All Patients. Percentage of Patients With Device Related Adverse Events
Percentage of participantseCoin Tibial Nerve Stimulation
Long-term Safety in All Patients. Percentage of Patients With Device Related Adverse Events21
SecondaryLong-term Safety in All Patients. Percentage of Patients With Device Related Adverse Events

All adverse events will be reported in all patients up to 257 weeks after implantation.

Time frame:
257 weeks after implantation
Reported as:
Number · Percentage of participants
Long-term Safety in All Patients. Percentage of Patients With Device Related Adverse Events
Percentage of participantseCoin Tibial Nerve Stimulation
Long-term Safety in All Patients. Percentage of Patients With Device Related Adverse Events23

Adverse events

Collected over 257 weeks post-implantation. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
eCoin Tibial Nerve Stimulation2/133 (1.5%)4/133 (3%)40/133 (30.1%)
Most frequent serious events
Most frequent serious events
EventeCoin Tibial Nerve Stimulation
Implant site infectionInfections and infestations2/133
Postoperative wound infectionInfections and infestations1/133
Contact DermatitisSkin and subcutaneous tissue disorders1/133
Most frequent other events
Showing 10 of 15
Most frequent other events
EventeCoin Tibial Nerve Stimulation
Postoperative wound infectionInfections and infestations7/133
Device stimulation issueProduct Issues6/133
Incision site painInjury, poisoning and procedural complications5/133
Device dislocationProduct Issues3/133
Wound dehiscenceInjury, poisoning and procedural complications3/133
Pain in extremityMusculoskeletal and connective tissue disorders3/133
Device malfunctionProduct Issues2/133
Incision site erythemaInjury, poisoning and procedural complications2/133
Implant site swellingGeneral disorders2/133
Skin irritationSkin and subcutaneous tissue disorders2/133

Baseline characteristics

Age, Continuous
Age, Continuous(years)eCoin Tibial Nerve Stimulation
Mean64.0 ± 11.0
Sex: Female, Male
Sex: Female, Male(Participants)eCoin Tibial Nerve Stimulation
Female131
Male2
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)eCoin Tibial Nerve Stimulation
Hispanic or Latino22
Not Hispanic or Latino101
Unknown or Not Reported10
Race (NIH/OMB)
Race (NIH/OMB)(Participants)eCoin Tibial Nerve Stimulation
American Indian or Alaska Native3
Asian2
Native Hawaiian or Other Pacific Islander1
Black or African American6
White112
More than one race0
Unknown or Not Reported9
Region of Enrollment
Region of Enrollment(participants)eCoin Tibial Nerve Stimulation
United States133
Urgency Urinary Incontinence (UUI) Episodes
Urgency Urinary Incontinence (UUI) Episodes(episodes/day)eCoin Tibial Nerve Stimulation
Mean4.32 ± 3.08
Urinary Voids
Urinary Voids(voids/day)eCoin Tibial Nerve Stimulation
Mean13.06 ± 2.67
Urgency Episodes
Urgency Episodes(episodes/day)eCoin Tibial Nerve Stimulation
Mean8.20 ± 3.65

3 further baseline measures are reported on the registry.

08

Study locations

15 sites
  • Kaiser Permanente
    Downey, California 90242, United States
  • Sequoia Urology Center
    Redwood City, California 94062, United States
  • Kaiser Permanente
    San Diego, California 92110, United States
  • Sansum Clinic
    Santa Barbara, California 93105, United States
  • SurgOne PC
    Englewood, Colorado 80113, United States
  • Urology Associates of Norwalk
    Norwalk, Connecticut 06850, United States
  • Florida Bladder Institute
    Naples, Florida 34109, United States
  • North Shore Medical Group
    Skokie, Illinois 60076, United States
  • UnityPoint Clinic
    Waterloo, Iowa 50703, United States
  • Chesapeake Urology
    Owings Mills, Maryland 21117, United States
  • Adult & Pediatric Urology
    Omaha, Nebraska 68114, United States
  • Manhattan Medical Research
    New York, New York 10016, United States
  • Alliance Urology Specialists
    Greensboro, North Carolina 27403, United States
  • The Institute for Female Pelvic Medicine & Reconstructive Surgery (FPM Institute)
    Allentown, Pennsylvania 18103, United States
  • South Carolina OB/GYN
    Columbia, South Carolina 29201, United States
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Sep 2018 to primary completion in Apr 2020, 19 months.

Results were first posted in Jul 2021, 1 year 3 months after primary completion.

Of 41 industry-sponsored interventional studies with no phase under Urinary Bladder, Overactive, half reached primary completion within 13 months of starting (the median), counting those still running; a quarter within 8 and three quarters within 25. This study's 19 months is above that.

Counting every sponsor, half of 176 studies reached it within 19 months; a quarter within 10 and three quarters within 40.

How these figures are worked out, and which studies are left out of them.

Registered
May 22, 2018
First posted
Jun 14, 2018
StartActual
Sep 4, 2018
Primary completionActual
Apr 12, 2020
CompletionActual
Sep 18, 2024
Results first posted
Jul 30, 2021
Last update
Oct 2, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 2, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03556891
Lead sponsor
Valencia Technologies Corporation
Responsible party
Sponsor
First posted
Jun 14, 2018
Start date
Sep 4, 2018
Primary completion
Apr 12, 2020
Completion
Sep 18, 2024
Results posted
Jul 30, 2021
Last update
Oct 2, 2025

Study contacts

Scott MacDiarmid, MD
principal investigator · Alliance Urology

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion